We rank companies based on fund manager, research analyst and news sentiment
BCAB stock icon

BioAtla
BCAB

$2.53
3.62%
 

About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Employees: 65

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

144% more call options, than puts

Call options by funds: $33K | Put options by funds: $13.5K

31% more capital invested

Capital invested by funds: $50.5M [Q3] → $66.4M (+$15.9M) [Q4]

4% less funds holding

Funds holding: 81 [Q3] → 78 (-3) [Q4]

5.62% less ownership

Funds ownership: 61.98% [Q3] → 56.35% (-5.62%) [Q4]

11% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 27

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
177%
upside
Avg. target
$10.25
305%
upside
High target
$12
374%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
JMP Securities
Reni Benjamin
374%upside
$12
Market Outperform
Reiterated
28 Mar 2024
HC Wainwright & Co.
Arthur He
177%upside
$7
Buy
Maintained
27 Mar 2024
JMP Securities
Reni Benjamin
374%upside
$12
Market Outperform
Reiterated
5 Dec 2023
HC Wainwright & Co.
Arthur He
295%upside
$10
Buy
Maintained
8 Nov 2023

Financial journalist opinion

Based on 3 articles about BCAB published over the past 30 days